Mobile website
Clinical Research
Real-time fluorescence quntitative PCR in analysis of HMGA2 expression in CML patients and its clinical significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Abstract Objective:To examine the expression of high mobility group A2 (HMGA2) mRNA in the peripheral blood of chronic myeloid leukemia (CML) patients and the related clinical characteristics, and to explore its role and clinical significance in CML progress. Methods: Peripheral blood samples of 24 CML patients and 5 volunteers, who had been diagnosed in our hospital from Jan. 2006 to Feb. 2008, were collected in the present study (all the patients and volunteers signed paper of informed consent and the study was approved by ethics committee). BCR/ABL fusion gene expression in CML bone samples was detected by fluorescence in situ hybridization (FISH). HMGA2 mRNA expression was examined by real-time fluorescence quantitative PCR (RTQ-PCR). Rank sum test was used to assess the HMGA2 gene transcription differences between CML-CP and CML-AP/BP patients. Correlation analyses were done using Spearman’s correlation test to explore the correlation between HMGA2 expression, BCR/ABL fusion gene expression, and hematological parameters in peripheral blood of CML patients. Results: We found that (58.08±39.21)% leukemia cells were BCR/ABL fusion gene-positive in 12 CML-CP patients, and the relative quantitative expression of HMGA2 gene was 2.39±1.86. Meanwhile, (87.50±16.21)% leukemia cells were BCR/ABL fusion gene-positive in 12 CML-AP/BP patients, and HMGA2 gene relative quantitative expression was 91.78±14.07. HMGA2 gene transcriptions between CML-CP and CML-AP/BP patients were significantly different (Z=-4.157, P<0.01). HMGA2 gene transcription in CML-AP/BP patients was positively correlated with the numbers of blast cells in the peripheral blood (r=0.636, P=0.017). Conclusion: HMGA2 gene transcription level in CML-AP/BP patients is higher than that in CML-CP patients, indicating HMGA2 may be a reliable indicator in estimating the development, prognosis and clinical treatment outcome of CML patients.
Keywords:
Project Supported:
Project supported by the Science and Technology Key Task Program of Guangdong Province（No. 2006Z3-E0401）
Clc Number:
